Please login to the form below

Not currently logged in
Email:
Password:

FDA warns pharma over misleading web ads

The FDA has issued warning letters to 14 pharma companies over misleading information in sponsored links on search engines

The US Food and Drug Administration (FDA) has issued warning letters to 14 pharma companies after routine monitoring found sponsored links on major internet search engines containing misleading information about drugs.

Routine monitoring and surveillance by the Division of Drug Marketing, Advertising, and Communications (DDMAC) of the FDA discovered that several pharmaceutical companies are using platforms such as Google and Yahoo to advertise their products in the form of sponsored links. DDMAC claims these links are misleading as they fail to communicate any risks associated with the use of the product. In some instances, the omission relates to advertised drugs that carry Boxed Warnings.

Several of the adverts contain links to websites dedicated to the products; however, DDMAC said that the link "is insufficient to mitigate the misleading omission of risk information from these promotional materials".

The letters also highlighted that by failing to use the required established name, pharma companies were in breach of the Federal Food, Drug, and Cosmetic Act and FDA implementing regulations.

In the letters, dated March 26, DDMAC has requested that each company ceases to publish promotional materials, such as those outlined in the letter immediately. The pharma companies concerned have until April 9, to submit a written response stating whether they intend to comply with the request, listing all promotional materials in use for each affected product, identifying the promotional materials that violate the regulations and explaining their plan for discontinuing the use of such materials.

7th April 2009

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
6 critical success factors for flawless execution of a rapid first commercial launch
Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....